These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27716874)

  • 21. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
    Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
    Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
    Wick A; Felsberg J; Steinbach JP; Herrlinger U; Platten M; Blaschke B; Meyermann R; Reifenberger G; Weller M; Wick W
    J Clin Oncol; 2007 Aug; 25(22):3357-61. PubMed ID: 17664483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
    Brada M; Viviers L; Abson C; Hines F; Britton J; Ashley S; Sardell S; Traish D; Gonsalves A; Wilkins P; Westbury C
    Ann Oncol; 2003 Dec; 14(12):1715-21. PubMed ID: 14630674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temozolomide as first-line agent in treating high-grade gliomas: phase II study.
    Chibbaro S; Benvenuti L; Caprio A; Carnesecchi S; Pulerà F; Faggionato F; Serino D; Galli C; Andreuccetti M; Buxton N; Gagliardi R
    J Neurooncol; 2004; 67(1-2):77-81. PubMed ID: 15072451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
    Noël G; Schott R; Froelich S; Gaub MP; Boyer P; Fischer-Lokou D; Dufour P; Kehrli P; Maitrot D
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):749-55. PubMed ID: 21300471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
    Balmaceda C; Peereboom D; Pannullo S; Cheung YK; Fisher PG; Alavi J; Sisti M; Chen J; Fine RL
    Cancer; 2008 Mar; 112(5):1139-46. PubMed ID: 18246536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
    Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
    J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of temozolomide in patients with progressive low-grade glioma.
    Quinn JA; Reardon DA; Friedman AH; Rich JN; Sampson JH; Provenzale JM; McLendon RE; Gururangan S; Bigner DD; Herndon JE; Avgeropoulos N; Finlay J; Tourt-Uhlig S; Affronti ML; Evans B; Stafford-Fox V; Zaknoen S; Friedman HS
    J Clin Oncol; 2003 Feb; 21(4):646-51. PubMed ID: 12586801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma.
    Zhou Z; Howard TA; Villano JL
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):1043-1046. PubMed ID: 28791452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
    Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
    Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
    Aoki T; Mizutani T; Ishikawa M; Sugiyama K; Hashimoto N
    Int J Clin Oncol; 2003 Oct; 8(5):301-4. PubMed ID: 14586755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
    Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
    Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
    Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
    J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic history of low-grade gliomas before and after temozolomide treatment.
    Ricard D; Kaloshi G; Amiel-Benouaich A; Lejeune J; Marie Y; Mandonnet E; Kujas M; Mokhtari K; Taillibert S; Laigle-Donadey F; Carpentier AF; Omuro A; Capelle L; Duffau H; Cornu P; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
    Ann Neurol; 2007 May; 61(5):484-90. PubMed ID: 17469128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).
    Hwang K; Kim TM; Park CK; Chang JH; Jung TY; Kim JH; Nam DH; Kim SH; Yoo H; Hong YK; Kim EY; Lee DE; Joo J; Kim YJ; Choe G; Choi BS; Kang SG; Kim JH; Kim CY
    Cancer Res Treat; 2020 Apr; 52(2):505-515. PubMed ID: 31671938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
    Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
    Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
    Harris MT; Rosenthal MA; Ashley DL; Cher L
    J Clin Neurosci; 2001 Jul; 8(4):325-7. PubMed ID: 11437571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.
    Taliansky-Aronov A; Bokstein F; Lavon I; Siegal T
    J Neurooncol; 2006 Sep; 79(2):153-7. PubMed ID: 16855865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment.
    Yaman E; Buyukberber S; Uner A; Coskun U; Akmansu M; Benekli M; Yamac D; Ozturk B; Kaya AO; Yildiz R; Ozkan S; Gunel N
    Onkologie; 2008 Jun; 31(6):309-13. PubMed ID: 18547971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.